ArticleClinical epidemiology2026
The Danish Lymphoid Cancer Research (DALY-CARE): Genetic Cohort Profile.
Article in Clinical epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Purpose: The Danish Lymphoid Cancer Research (DALY-CARE) Genetic Cohort was established to support research into how genetic factors influence clinical outcomes in lymphoid cancers (LCs), including disease progression, treatment response, toxicity, and survival. Individual-level genetic data were combined with detailed clinical information from national health registers, hospital-based electronic health records (EHR), laboratory data, and pathology reports. The cohort enables large-scale studies of genetic susceptibility, disease course, and therapy-related outcomes in LCs and provides a platform for genetic epidemiology and future multi-omics research within a unified data infrastructure. Participants: The genetic cohort includes 8675 genotyped individuals drawn from the broader DALY-CARE population (n=74,251, as of April 2025), including individuals diagnosed with LCs such as diffuse large B-cell lymphoma (DLBCL, n=1349), chronic lymphocytic leukemia (CLL, n=1245), multiple myeloma (MM, n=1209), follicular lymphoma (FL, n=704), Hodgkin lymphoma (HL, n=407), Waldenström macroglobulinemia and lymphoplasmacytic lymphoma (WM/LPL, n=368), marginal zone lymphoma (MZL, n=287), and precursor states such as monoclonal gammopathy of undetermined significance (MGUS, n=1299). Descriptive Findings: Hematologic malignancy was the most frequent cause of death (30%), followed by infections (27%) and other cancers (15%). Polypharmacy, as a more sensitive proxy for comorbidity than hospital diagnosis codes, was substantial (median 7-8 drugs pre-diagnosis). Frequently observed comorbidities were hypertension (47%), cardiovascular disease (16%), cerebrovascular disease (11%) and type 2 diabetes (10%). Kinship analysis identified limited relatedness (41 parent-offspring, 51 siblings), while ancestry inference confirmed predominantly Northwestern European descent (97%). Future Opportunities: The DALY-CARE Genetic Cohort provides a foundation for studying genetic and clinical determinants of LC outcomes. Integration of genotype data with EHR and national health registers enables exploration of germline risk and protective variants. Future expansions will integrate additional omics data types, such as whole-genome sequencing, transcriptomics, proteomics, and immunophenotyping, positioning the cohort as a national platform for multi-omics research in LC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.